NovoCure (NVCR) Cash from Investing Activities (2014 - 2026)

NovoCure (NVCR) has reported Cash from Investing Activities for 13 consecutive years, with -$6.4 million the latest figure, recorded in Q2 2026.

• Quarterly Cash from Investing Activities fell 117.72% year-over-year to -$6.4 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $409.1 million (up 2238.43% YoY) and the FY2025 annual result came in at $437.3 million, up 411.8% from the prior year.
• Cash from Investing Activities declined to -$6.4 million in Q2 2026 per NVCR's latest filing, from $7.7 million in the prior quarter.
• Over the last five years, Cash from Investing Activities for NVCR reached as high as $336.3 million in Q4 2025 and fell as low as -$374.4 million in Q2 2024.
• A 5-year average of $19.0 million and a median of $9.0 million in 2024 frame the typical range for Cash from Investing Activities.
• Annual changes were most pronounced in 2022 — Cash from Investing Activities soared 6049.47% — and 2024, when it sank 2594.39%.
• Year by year, Cash from Investing Activities stood at -$128.1 million in 2022, then surged by 176.92% to $98.5 million in 2023, then slumped by 122.55% to -$22.2 million in 2024, then jumped by 1614.23% to $336.3 million in 2025, then tumbled by 101.9% to -$6.4 million in 2026.
• According to Business Quant data, Cash from Investing Activities over the past three periods registered -$6.4 million, $7.7 million, and $336.3 million for Q2 2026, Q1 2026, and Q4 2025 respectively.